Answers are grounded in this paper and cite their sources.
Solid organ transplantation (SOT) presents a unique intersection of life-saving opportunity and infectious risk. This review examines the implications of hepatitis B, C, and E from both donor and recipient perspectives and provides updated evidence-based management strategies. Advances in antiviral therapies have enabled the safe utilization of HBV- and HCV- infected donors, which can expand the donor pool without compromising recipient outcomes. For HBV, nucleos(t)ide analogs provide effective prophylaxis and treatment, and emerging data support using HBsAg+ donors in HBV-naive recipients with proper management. In the case of HCV, direct-acting antivirals (DAAs) have revolutionized transplant medicine, allowing the routine use of HCV-viremic donors. Both preemptive and prophylactic treatment strategies are discussed, with growing support for short-course DAA regimens in cardiothoracic transplant. HEV, though less commonly screened, poses a risk for chronic infection in immunocompromised hosts and can lead to graft dysfunction or rejection. Ribavirin remains the mainstay of treatment, and the potential for donor-derived HEV transmission highlights the importance of surveillance and, where available, screening protocols. This review proposes practical algorithms for pre- and post-transplant management and outlines future directions in vaccine development, viral screening, and antiviral therapies. A tailored, virus-specific approach informed by both donor and recipient virologic status is essential to optimize patient and graft outcomes while ensuring safe expansion of the donor organ pool.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: